GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most ...

Individuals 65-and-up, particularly those with other health conditions, are among those most-at-risk for severe cases of RSV.

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD.

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

Here’s what you need to know. While most people who contract RSV can recover at home, some are sick enough to be admitted to ...

Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Which is why doctors and health experts are encouraging people to get the RSV vaccine now. That includes. Dr. Eryn Hart from ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...